Substance abuse in patients with attention-deficit/hyperactivity disorder

MedGenMed Medscape General Medicine

Volumn 10, Issue 1, 2008, Pages

  Bukstein, Oscar ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; COCAINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENCE; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG MISUSE; FEEDBACK SYSTEM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERVIEW; MENTAL DISEASE; PATIENT MONITORING; PSYCHOSOCIAL CARE; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE; SUDDEN DEATH; SUSTAINED RELEASE FORMULATION; SYMPTOMATOLOGY; TIME MANAGEMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; ADDICTION; ADOLESCENT; ADULT; METHODOLOGY; REVIEW; RISK FACTOR;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; HUMANS; RISK FACTORS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 39049102086     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652-1658.
2. Molina BS, Pelham WE. Childhood predictors of adolescent substance abuse in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112:497-507.
3. Wilens TE, Biederman J. Alcohol, drugs, and attention-deficit/ hyperactivity disorder a model for the study of addictions in youth. J Psychopharmacol. 2006;20:580-588.
4. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003; 111: 179-185.
5. Wilens TE, Gignac M, Swezey A. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414.
6. Emergency department visits involving ADHD stimulant medications. The New DAWN Report, Issue 29, 2006. Available at: https://dawninfo.samhsa.gov/files/TNDR09ADHDmedsForHtml.pdf Accessed January 15, 2008.
7. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160:1041-1052.
8. Khantzian EJ. The self-medication hypothesis of substance use disorders: reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231-244.
9. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187-201.
10. American Academy of Child and Adolescent Psychiatry Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
11. Kessler RC, Adler L, Ames M, et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35:245-256.
12. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales. New York: Multi-Health Systems; 1999.
13. Brown TE. Brown Attention-Deficit Disorder Scales, Manual. San Antonio: Harcourt Brace; 1996.
14. American Academy of Pediatrics, Division of Child Health Research. Periodic survey of fellows. No. 31. Available at: http://www.aap.org/ research/periodicsurvey/ps31a.htm Accessed January 15, 2008.
15. Knight JR, Sherritt L, Shrier LA, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156:607-614.
16. Bastiaens L, Riccardi K, Sakhrani D. The RAFFT as a screening tool for adult substance-use disorders. Am J Drug Alcohol Abuse. 2002;28:681-691.
17. Kulig JW, Committee on Substance Abuse. Tobacco, alcohol and other drugs: the role of the pediatrician in prevention, identification, and management of substance abuse. Pediatrics. 2005;115:816-821.
18. Passik SD, Kirsh KL, McDonald MV, et al. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage. 2000; 19:274-286.
19. Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry 2006;59:258-264.
20. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity disorder and substaace abuse: diagnostic and therapeutic considerations. Ann N Y Acad Sci. 2001;931:251-270.
21. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87:20-29.
22. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol. 1998;6-367-374.
23. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387-395.
24. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5:833-841.
25. Greenhill LL, Muniz R,.Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:817-823.
26. American Academy of Pediatrics Subcommittee on Attention Deficit/ Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guidelines: treatment of the school-aged child with attention deficit/hyperactivity disorder. Pediatdcs. 2001; 108:1033-1044.
27. Brown RT, Amler RW, Freeman WS, et al. Treatment of aftention deficit/ hyperactivity disorder overview of the evidence. Pediatrics. 2005; 115:e749-e757.
28. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8:4.
29. Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children. Drugs. 2006;66:1117-1126.
30. Jasinski D, Krishnan S. Pharmacokinetics of oral lisdexamfetamine dimesylate (LDX; NRP104) vs damphetamine in healthy adults with a history of stimulant abuse. Program and abstracts of the US-Psychiatric and Mental Health Congress; November 17, 2006; New Orleans, Louisiana.
31. Jasinski D, Krishnan S, Kehner G. Abuse liability of intravenous lisdexamfetamine (LDX; NRP 104). Program and abstracts of the 2006 Annual Meeting of the Society for Developmental and Behavioral Pediatrics; September 16-18, 2006; Philadelphia, Pennsylvania.
32. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-463.
33. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psych. 2007;62:970-976.
34. Findling RL, Childress AC, Krishnan S, et al. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/ hyperactivity disorder. Program and abstracts of the 2007 Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, California.
35. US Food and Drug Administration. Risks for ADHD drugs outlined in patient guides. Consumer Update. Posted April 23, 2007. Available at: http:/twww.fda.gov/consumer/updates/adhd042307.html Accessed January 15, 2008.
36. US Food and Drug Administration. FDA Patient Safety News: Show #63, May 2007. Cardiovascular and psychiatric risks with ADHD drugs. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/ printer.cfm?id=519 Accessed January 15, 2008.